Background
Progestagens used in HRT have substantially distinct pharmacological pro-files.
The novel progestin drospirenone has antimineralocorticoid properties which could have beneficial as well unfavorable effects on cardiovascular out-comes.
Active safety surveillance using a prospective, controlled cohort study design is a reliable method to compare drug utilization and safety of new and established drugs under “real-life conditions”.
